This article is more than 5 years old. Information may no longer be current.

Jetrea approved for treatment of symptomatic vitreomacular adhesion in Canada

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Canada has become the first market outside the United States and Europe to approve Jetrea for the treatment of symptomatic vitreomacular adhesion, according to a news release.

Jetrea (ocriplasmin, ThromboGenics) was approved by Health Canada via priority review within 180 days of the new drug submission. Alcon, which holds non-U.S. marketing rights for the drug, will handle commercialization in Canada, the release said.

Alcon launched Jetrea in the United Kingdom in April, followed by Germany, Denmark, Finland, Norway and Sweden. ThromboGenics launched the product in the United States in January.

“We are looking forward to announcing further approvals of Jetrea in other markets shortly,” Patrik De Haes, CEO of ThromboGenics, said in the release.